Entries by Thomas Gabrielczyk

DeepLife raises US$10m in Series A financing

Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens Innovation Santé with participation from Beiersdorf Venture Capital, Prunay Group, and existing investors.

,

Membrane target triggers inflammation

Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.

Citryll BV raises €85m in Series B financing

Dutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.

French Ipsen inks US$610m biobucks deal with Biomunex SA

French Ipsen has exclusively licensed BMX-502, a T-cell engager (TCE) from Biommunex SA, which prevents common problems of TCEs such as cytokine release syndrome and T cell exhaustion by using a specific mucosal T cell subpopulation abundant in the human body.

Obesity gene therapy enters Phase I testing

After securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.